VYVGART Hytrulo, illustration of injection vial form (not a photo of the actual pack)

Illustrative image.

VYVGART Hytrulo

Efgartigimod Alfa And Hyaluronidase‑qvfc

Prescription required

$16070.00

40mg/20ml · 1 vial

BrandBranded medicine· By argenx

Strength

Choose a pack

  • Selected pack

Packs in this delivery

1

Test mode: no payment is taken. View cart

Ships cold, in insulated packing

This medicine ships in insulated packing with coolant and carries its own shipping charge, shown at checkout.

Prescription required

Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.

40mg/20ml

180mg/ml

About VYVGART Hytrulo

Overview

VYVGART Hytrulo contains efgartigimod alfa and hyaluronidase-qvfc and is given as an injection under the skin. It is used to treat adults with generalized myasthenia gravis (gMG) or chronic inflammatory demyelinating polyneuropathy (CIDP). Efgartigimod alfa lowers the amount of immunoglobulin G (IgG) antibodies circulating in the blood, while hyaluronidase helps the medicine spread and be absorbed under the skin.

What it treats

Generalized myasthenia gravis (gMG) in adults. Chronic inflammatory demyelinating polyneuropathy (CIDP) in adults.

Safety information

Side effects

Common side effects include injection-site reactions. Respiratory tract infections, headache and urinary tract infections were also common in patients with gMG treated with efgartigimod alfa-fcab. Serious infections, allergic reactions and injection-related reactions can occur. Contact your doctor if you develop signs or symptoms of infection; treatment may need to be delayed or withheld until the infection resolves. Seek urgent medical attention for a severe allergic or injection-related reaction. Reported allergic reactions include anaphylaxis, low blood pressure causing fainting, swelling (angioedema), difficulty breathing, rash and hives.

When to call your doctor

- Trouble breathing, seek medical attention immediately. - Swelling of the face, lips, tongue or throat, seek medical attention immediately. - Fainting, seek medical attention immediately. - Rash or hives, seek medical attention immediately.

If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.

Before taking this medicine

Do not use VYVGART Hytrulo if you have had a serious allergic reaction to efgartigimod alfa products, hyaluronidase or any other ingredient in this medicine. Reactions have included anaphylaxis and low blood pressure leading to fainting. Treatment should be delayed if you have an active infection. You should be monitored for signs of infection during treatment. If a serious infection develops, it should be treated, and your healthcare professional may withhold VYVGART Hytrulo until it has resolved. Seek medical attention if you develop an allergic reaction, such as swelling, difficulty breathing, rash, hives or fainting. Injection-related reactions also require assessment. After a severe reaction, your healthcare professional should weigh the risks and benefits before giving the medicine again. After a mild or moderate reaction, further treatment may require close observation and other precautions.

Interactions

VYVGART Hytrulo may reduce the effectiveness of medicines that bind to the human neonatal Fc receptor (FcRn). Tell your doctor about your other medicines so they can check for this interaction and closely monitor their effectiveness. If long-term use of an affected medicine is essential, your doctor may consider stopping VYVGART Hytrulo and using an alternative treatment.

Using VYVGART Hytrulo

Dosing

Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.

Storage

Store in the original carton below 25°C, protected from light, unless the pack states refrigeration. Do not freeze. Keep all medicines out of the sight and reach of children.

Clinical information on this page is summarised from the US FDA label VYVGART HYTRULO (EFGARTIGIMOD ALFA AND HYALURONIDASE (HUMAN RECOMBINANT)) INJECTION, SOLUTION [ARGENX US] (DailyMed, retrieved 19 September 2026).

Reviews

No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.

  • Every prescription order is checked by a licensed pharmacist before dispensing.
  • Payment pages are encrypted and card details never reach our servers.
  • We ship internationally, with cold-chain packing where a medicine needs it.

Related medicines